Warrant Terms and Conditions - The warrant allows the holder to purchase a total of ______________ shares of common stock or exchange warrants at an exercise price of $0.0001[1] - The exercise period for the warrant extends until 11:59 p.m. New York time on the expiration date or 30 days after notice of exercise conditions being met[1] - The holder must deliver the aggregate exercise price in cash via wire transfer within one trading day of the exercise notice[2] - The company is responsible for all fees and expenses related to the transfer agent and issuance of warrant shares or exchange warrants[3] - If the company fails to deliver the securities by the delivery date, it must compensate the holder for any losses incurred due to a buy-in[6] - The exercise price for warrant shares and exchange warrants is subject to adjustment as specified in the agreement[5] - The company must ensure its transfer agent participates in the DTC Fast Automated Securities Transfer Program while the warrant is outstanding[6] - No fractional warrant shares or exchange warrants will be issued; amounts will be rounded down to the nearest whole number[3] - The holder has the right to rescind an exercise if the company fails to deliver the applicable number of shares by the delivery date[6] - The company must promptly resolve any disputes regarding the exercise price or calculation of warrant shares or exchange warrants[7] Ownership and Issuance Limitations - The Company has established a Maximum Percentage of beneficial ownership at 4.99% or 9.99% for the Holder and Attribution Parties, limiting the exercise of Warrants to prevent exceeding this threshold[8] - The Primary Market Limitation is set at 19.99% of the outstanding shares of Common Stock before the issuance of shares upon exercise of the Warrant[13] - The Required Reserve Amount mandates the Company to reserve at least 100% of the maximum number of shares necessary to satisfy obligations under outstanding Warrants[14] - In the event of an Authorized Share Failure, the Company is required to take commercially reasonable actions to increase the number of authorized shares to meet the Required Reserve Amount[16] - The Company must confirm the number of outstanding shares of Common Stock to the Holder within two business days upon request[11] Pricing and Valuation - The cashless exercise option allows the Holder to receive Warrant Shares without cash payment if there is no effective registration statement available[17] - The Bid Price for the Common Stock is determined based on the first applicable clause, including trading market prices reported by Bloomberg[19] - The VWAP (Volume Weighted Average Price) is calculated based on trading market data, ensuring accurate pricing for the Common Stock[21] - The Company must return any excess Exercise Price paid by the Holder for Reduction Shares if the exercise would exceed the Maximum Percentage[10] - The Company is responsible for ensuring compliance with Section 13(d) of the Exchange Act regarding beneficial ownership calculations[13] - The Company may voluntarily adjust the Exercise Price of the Warrant at any time deemed appropriate by the Board of Directors[22] - If the Company subdivides its outstanding shares of Common Stock, the Exercise Price will be proportionately reduced, and the number of Warrant Shares will be proportionately increased[23] Rights and Obligations - In the event of any asset distribution to Common Stock holders, the Holder is entitled to participate as if they had exercised the Warrant[25] - If the Company grants Purchase Rights, the Holder can acquire the same proportion of Purchase Rights as if they had exercised the Warrant[26] - The Company cannot enter into a Fundamental Transaction without the Successor Entity assuming all obligations under the Warrant[27] - The Company will not avoid the observance of any terms of the Warrant through amendments or reorganizations[28] - The Holder is not deemed a stockholder and does not have voting rights until the Warrant is exercised[29] - The Company will issue a new Warrant upon transfer, loss, theft, or mutilation of the original Warrant[30][32][34] - Notices required under the Warrant must be delivered in writing to specified addresses[35] - The Company will provide prompt written notice of all actions taken pursuant to the Warrant, including adjustments to the Exercise Price and any dividend distributions[36] - The Company may amend or waive provisions of the Warrant only with the written consent of the Holder[37] - The Warrant is governed by the laws of the State of New York, and the Company submits to the jurisdiction of New York courts[38] - In case of disputes regarding the Exercise Price or Warrant Shares, the Company will submit calculations to an independent investment bank or accountant for resolution[39] - The remedies provided in the Warrant are cumulative and include the right to seek injunctive relief without showing economic loss[40] - The Warrant and Warrant Shares may be transferred without the Company's consent, as outlined in Section 7(a)[41] - If any provision of the Warrant is deemed invalid, the remaining provisions will still be enforceable[42] - The Company must publicly disclose any material, nonpublic information received in accordance with the Warrant[43] Definitions and Legal Considerations - Definitions of key terms such as "Common Stock," "Exercise Conditions," and "Change of Control" are provided for clarity[44][48] - The Company acknowledges that a breach of obligations may cause irreparable harm to the Holder, justifying the right to seek an injunction[40] - The Company is involved in a Fundamental Transaction, which includes mergers, asset sales, or stock purchase agreements that may result in a change of control[54] - The definition of "Subject Entity" includes any person or group that may acquire significant ownership or control over the Company's shares[59] - The Principal Market for the Company's Common Stock is The Nasdaq Capital Market[58] - The Company has established a standard settlement period for its Common Stock transactions, which is defined in terms of Trading Days[61] - The exercise price for purchasing shares of Common Stock is set at $0.01 per share[66] - The Company is required to deliver Warrant Shares or Exchange Warrants upon exercise of the warrants[68] - The definition of "Parent Entity" refers to an entity that controls the Company and is publicly traded[56] - The Company must comply with regulations regarding the issuance of shares to avoid circumventing the intent of the Fundamental Transaction definition[54] - The term "Options" refers to rights or warrants to purchase shares of Common Stock or Convertible Securities[55] - The Company is represented by its Chief Executive Officer, Joshua Disbrow, in official documents[65]

Core Insights - Aytu BioPharma reported net revenue of $15.2 million for Q2 2026, with ADHD portfolio revenue at $13.2 million, reflecting a slight decrease due to a strategic shift towards launching EXUA, the first FDA-approved 5HT1A agonist for treating major depressive disorder (MDD) [12][18] - The commercial launch of EXUA is supported by a targeted marketing strategy, including a strong sales team and the RX Connect platform to ensure patient access and minimize costs [13][19] - Management emphasized a cautious approach towards expanding the salesforce, contingent on achieving profitability and cash flow from EXUA sales [13][22] Financial Performance - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year, with ADHD portfolio revenue at $13.2 million compared to $13.8 million [18] - Gross margin decreased to 63.5% due to transition-related expenses, but would have been 67.4% excluding a $600,000 inventory write-down [13][18] - The company reported a net loss of $10.6 million or $1.05 per share, compared to a net income of $0.8 million or $0.13 per share in the prior year [18] Product Launch and Strategy - EXUA was launched with early prescriptions written in 27 states, and over 100 doctors have prescribed it within the first month [12][19] - The RX Connect platform is designed to minimize administrative burdens for patients and prescribers, ensuring predictable coverage for commercially insured patients [13][19] - The marketing strategy includes a mix of personal and non-personal approaches, focusing on high-volume antidepressant prescribers and leveraging insights from the RX Connect platform [19][23] Market Context - Major depressive disorder affects an estimated 21 million US adults, with a significant portion of patients failing to achieve remission with traditional SSRIs and SNRIs [16][19] - The ADHD portfolio continues to perform above expectations despite a slight revenue decrease, attributed to a strategic shift towards EXUA [18][19] - The company has $30 million in cash and cash equivalents, with ongoing investments focused on EXUA's launch [14][18]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

分组1 - Aytu BioPharma Inc. reported a quarterly loss of $1.05 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.26, marking an earnings surprise of -303.85% [1] - The company posted revenues of $15.17 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 26.27%, although this represents a decline from year-ago revenues of $16.22 million [2] - Aytu BioPharma shares have increased by approximately 4.2% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $12.7 million, and for the current fiscal year, it is -$0.54 on revenues of $52.63 million [7] - The Medical - Biomedical and Genetics industry, to which Aytu BioPharma belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Illumina, is expected to report quarterly earnings of $1.26 per share, reflecting a year-over-year increase of 46.5%, with revenues projected at $1.16 billion, up 4.6% from the previous year [9][10]

Financial Data and Key Metrics Changes - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year [20] - ADHD portfolio net revenue was $13.2 million, compared to $13.8 million in the prior year, remaining flat with the previous quarter [20] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in the previous quarter, but down from $2.7 million in the prior year [18][21] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [22] - The company reported a net loss of $10.6 million, compared to a net income of $0.8 million in the prior year [23] Business Line Data and Key Metrics Changes - The ADHD portfolio is experiencing a slight decrease in revenue due to a shift in marketing focus towards EXXUA and the introduction of generic competition [16][20] - The launch of an authorized generic for Adzenys has limited the impact of Teva's generic competition, with the authorized generic representing just under 20% of total prescriptions [17] - The pediatric portfolio saw a revenue increase due to reduced returns and stabilization of prescriptions, although it remains a non-core focus for the company [18] Market Data and Key Metrics Changes - The early feedback from patients on EXXUA has been positive, with reports of good tolerability and satisfaction [15] - Prescriptions for EXXUA have been written in 27 states, indicating broad market opportunity [14] - The majority of prescriptions are being filled through the RxConnect platform, with a favorable mix towards commercial insurance [48] Company Strategy and Development Direction - The company has launched EXXUA, the first FDA-approved 5-HT1A agonist for major depressive disorder, with a comprehensive commercial launch strategy focused on prescriber adoption and brand growth [4][31] - The marketing strategy includes a mix of personal and non-personal approaches, targeting high-volume antidepressant prescribers [11] - The company plans to maintain a focus on operational efficiency while scaling its promotional investments in line with performance [14][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the significant unmet need in the treatment of major depressive disorder, with 50%-60% of patients failing to achieve remission on current therapies [8][9] - The company expects to see a small initial ramp in EXXUA net revenue as it removes early access barriers and guarantees coverage for patients [26][27] - Management is optimistic about the early momentum of EXXUA and the potential for long-term growth, emphasizing the importance of cash flow for future expansion [39][40] Other Important Information - The company incurred a one-time FDA PDUFA fee of $400,000 during the quarter [23] - Adjusted EBITDA was -$0.8 million for the quarter, reflecting increased launch investments and a shift in marketing focus [25] - Cash and cash equivalents were $30 million at the end of the quarter, down from $32.6 million at the end of the previous quarter [25] Q&A Session Summary Question: Feedback from doctors on EXXUA prescriptions - Management noted mixed motivations for physicians to prescribe EXXUA, including interest in its mechanism of action and ease of prescribing through RxConnect [33][34][36] Question: Plans for sales force expansion - Management indicated that expansion would be unlikely in fiscal 2026 without sufficient cash flow and profitability to support it [38][39] Question: Direct-to-consumer campaign details - The campaign will focus on web-based strategies, including search engine optimization and social media, while maintaining compliance with FDA regulations [40][41] Question: Impact of weather on prescriptions - Management confirmed that recent weather events had a significant impact on prescriptions being filled and shipments to pharmacies, but supply issues have been resolved [46][53] Question: Supply ramp-up capabilities - Management assured that adequate supply is available to meet demand, with no issues anticipated in scaling production [53][54]

Financial Data and Key Metrics Changes - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year [20] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [21][22] - The company reported a net loss of $10.6 million, compared to a net income of $0.8 million in the prior year [23] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $13.2 million, a slight decrease from $13.8 million in the prior year and flat compared to the previous quarter [20][16] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in the previous quarter, but down from $2.7 million year-over-year [18][21] Market Data and Key Metrics Changes - Exxua prescriptions have been written in 27 states, with over 100 doctors prescribing it within the first month of launch [14][15] - The majority of prescriptions are being filled through the RxConnect platform, with a favorable mix towards commercial insurance [47] Company Strategy and Development Direction - The company has launched Exxua, the first FDA-approved 5-HT1A agonist for major depressive disorder, focusing on prescriber adoption and brand growth [4][31] - A comprehensive commercial launch strategy includes a motivated sales organization and targeted promotional efforts [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Exxua's market potential and early positive feedback from patients and prescribers [31][15] - The company is focused on maintaining operational efficiency while ramping up Exxua's market presence [29] Other Important Information - The company has a cash balance of $30 million as of December 31, 2025, down from $32.6 million at the end of the previous quarter [25] - The launch investment budget for Exxua has been reduced from $10 million to under $8 million due to execution efficiencies [29] Q&A Session Summary Question: Feedback from doctors prescribing Exxua - Early feedback indicates that physicians are motivated by the unique mechanism of action and the ease of prescribing through RxConnect [33][34] Question: Plans for sales force expansion - Management indicated that expansion would depend on achieving internal forecasts and cash flow, with no immediate plans for expansion in fiscal 2026 [38][39] Question: Direct-to-consumer campaign details - The campaign will focus on web-based strategies, including search engine optimization and social media, while maintaining compliance with regulations [40][41] Question: Impact of weather on prescription fulfillment - Weather has caused delays in prescriptions being filled, but the company has adequate supply to meet demand [46][53]

Financial Data and Key Metrics Changes - Net revenue for Q2 2026 was $15.2 million, down from $16.2 million in the prior year, with ADHD portfolio revenue at $13.2 million compared to $13.8 million last year [19][20] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [21][22] - The company reported a net loss of $10.6 million or $5 per share, compared to a net income of $0.8 million or $0.13 per share in the prior year [23][24] Business Line Data and Key Metrics Changes - ADHD net revenue was $13.2 million, flat compared to Q1 2026, despite a slight decrease from the previous year, attributed to a shift in marketing focus towards EXXUA [16][19] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in Q1 2026, but decreased from $2.7 million in the prior year [18][20] Market Data and Key Metrics Changes - The launch of EXXUA has seen prescriptions written from 27 states, with over 100 doctors prescribing it within the first month [13][14] - Most prescriptions are being filled through the RxConnect platform, with a significant portion also coming from retail pharmacies [46] Company Strategy and Development Direction - The company is focused on the commercial launch of EXXUA, the first FDA-approved 5-HT1A agonist for major depressive disorder, with a comprehensive strategy aimed at prescriber adoption and brand growth [4][31] - The marketing strategy includes a mix of personal and non-personal approaches, targeting high-volume antidepressant prescribers and leveraging the RxConnect platform for patient access [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early feedback from patients on EXXUA, noting good tolerability and satisfaction [15] - The company anticipates a gradual ramp-up in EXXUA net revenue as initial barriers to access are removed, with expectations for increased prescriptions ahead of revenue recognition [27][30] Other Important Information - The company incurred a one-time FDA PDUFA fee of $400,000 for Cotempla during the quarter [22] - Adjusted EBITDA was -$0.8 million for Q2 2026, down from $1.3 million in the prior year [25] Q&A Session Summary Question: Feedback from doctors prescribing EXXUA - Management noted mixed motivations for early prescriptions, including interest in the mechanism of action and ease of prescribing through RxConnect [33][34] Question: Expectations for sales force expansion - Management indicated that expansion would be unlikely in fiscal 2026, with triggers for expansion tied to achieving internal forecasts and cash flow [37][38] Question: Direct-to-consumer campaign details - The campaign will be web-based, focusing on search engine optimization and social media, while maintaining compliance with FDA regulations [39][40] Question: Impact of weather on prescription filling - Management confirmed significant weather impacts on script filling and shipments, but noted that supply issues have been corrected [44][51]

Revenue Performance - Net revenue for the three months ended December 31, 2025, decreased by $1.1 million, or 7%, compared to the same period in 2024, primarily due to a shift in marketing focus towards EXXUA[136]. - Net revenue for the six months ended December 31, 2025, decreased by $3.7 million, or 11%, compared to the same period in 2024, largely due to a $3.3 million increase in the first quarter of fiscal 2025 from successful vendor negotiations[137]. - EXXUA generated $241,000 in net revenue during the three months ended December 31, 2025, marking its successful launch as a key product[135]. - The ADHD Portfolio net revenue decreased by $600,000, or approximately 4%, during the three months ended December 31, 2025, compared to the same period in 2024[135]. - The Pediatric Portfolio net revenue decreased by $711,000, or approximately 30%, during the three months ended December 31, 2025, compared to the same period in 2024[135]. Operating Expenses and Profitability - Total operating expenses for the three months ended December 31, 2025, were $11.6 million, a decrease of $887,000 compared to the same period in 2024[134]. - Loss from operations for the three months ended December 31, 2025, was $1.97 million, compared to a loss of $1.70 million in the same period in 2024[134]. - Gross profit for the three months ended December 31, 2025, decreased by $1.2 million, or 11%, to $9.6 million, with a gross profit percentage of 63%, down from 66% in the same period of 2024[138]. - For the six months ended December 31, 2025, gross profit decreased by $4.0 million, or 17%, to $18.8 million, with a gross profit percentage of 65%, down from 69% in the same period of 2024[139]. Expenses Breakdown - Selling and marketing expenses increased by $0.7 million, or 14%, for the three months ended December 31, 2025, and by $0.4 million, or 4%, for the six months ended December 31, 2025, primarily due to labor and EXXUA launch costs[140]. - General and administrative expenses rose by $0.6 million, or 14%, for the three months ended December 31, 2025, and by $0.4 million, or 4%, for the six months ended December 31, 2025, driven by labor and service costs[141]. - Research and development expenses were zero for the three and six months ended December 31, 2025, compared to $0.5 million and $0.9 million for the same periods in 2024, due to a focus shift to commercial operations[142]. Interest and Financing - Interest expense decreased by $519,000, or approximately 48%, for the three months ended December 31, 2025, compared to the same period in 2024[134]. - Interest expense decreased by $0.5 million, or 48%, for the three months ended December 31, 2025, and by $1.0 million, or 48%, for the six months ended December 31, 2025, primarily due to paydowns of fixed payment arrangements[146]. - Net cash used in financing activities was $4.0 million for the six months ended December 31, 2025, primarily due to payments for fixed payment arrangements and the Eclipse Term Loan[160]. Cash Flow and Capital - Net cash provided by operating activities for the six months ended December 31, 2025, totaled $3.1 million, an increase of $1.3 million compared to $1.7 million in 2024[157]. - The company raised gross proceeds of $16.6 million in June 2025 from the issuance of common stock and prefunded warrants, intending to use the net proceeds for working capital and to commercialize EXXUA[153]. Strategic Focus - The company has indefinitely suspended active development of clinical programs and divested unprofitable operations to focus on core pharmaceutical products[127]. - The company expects EXXUA to serve as a major growth catalyst, targeting the over $22 billion U.S. prescription MDD market[126]. Financial Reporting and Compliance - The company has prepared its financial statements in accordance with U.S. GAAP, requiring estimates and judgments that affect assets, liabilities, revenue, and expenses[166]. - There are no off-balance sheet arrangements that could materially affect the company's financial condition or results of operations[167]. - The company is classified as a smaller reporting company and is not required to provide additional market risk information[168].

Financial Performance - Total net revenue for Q2 fiscal 2026 was $15.2 million, a decrease from $16.2 million in Q2 fiscal 2025[6] - The ADHD Portfolio net revenue was $13.2 million, down from $13.8 million in the prior year, attributed to a shift in marketing focus towards EXXUA[12] - Pediatric Portfolio net revenue decreased to $1.7 million from $2.4 million in the prior year, also due to reduced marketing efforts[13] - Net revenue for the three months ended December 31, 2025, was $15,165,000, a decrease of 6.5% from $16,221,000 in the same period of 2024[54] - Gross profit for the same period was $9,624,000, down from $10,786,000, reflecting a gross margin decrease[54] - The net loss for the three months ended December 31, 2025, was $10,584,000, compared to a net income of $788,000 in the same period of 2024[54] - Basic net loss per share for continuing operations was $(1.05), compared to a profit of $0.11 in the prior year[54] - The company reported a net loss of $10.6 million, compared to a net income of $0.8 million in the prior year period[16] Cash and Assets - Cash and cash equivalents stood at $30.0 million as of December 31, 2025, down from $31.0 million at June 30, 2025[17] - Cash and cash equivalents as of December 31, 2025, were $30,025,000, slightly down from $30,952,000[56] - Total assets decreased to $122,000,000 from $124,177,000, indicating a reduction in overall asset base[56] - Total stockholders' equity decreased to $14,201,000 from $18,966,000, reflecting a decline in equity position[56] Operating Expenses - Total operating expenses were $11,594,000, a reduction from $12,481,000, indicating a cost management effort[54] - Adjusted EBITDA was $(0.8) million, compared to $1.3 million in Q2 fiscal 2025, primarily due to investments in the EXXUA launch[17] - Adjusted EBITDA was $(802) for the current period, down from $1,273 in the previous year[58] - Interest expense decreased to $560 from $1,079 year-over-year[58] - Stock-based compensation expense increased to $283 from $151 year-over-year[58] - Depreciation and amortization expenses decreased to $885 from $1,292 year-over-year[58] - The company incurred restructuring costs of $1,317 in the previous year, which were not present in the current period[58] EXXUA Launch and Strategy - EXXUA generated initial net revenue of $0.2 million during the quarter, following its commercial launch in mid-December 2025[11] - Aytu has deployed a 40+ person sales force targeting approximately 5,500 healthcare practitioners for EXXUA[9] - The company aims to capture a share of the over $22 billion U.S. prescription MDD market with EXXUA[5] - Management emphasized a comprehensive launch strategy for EXXUA, focusing on prescriber adoption and brand growth[8] Risk and Safety Monitoring - The company is actively monitoring for risks associated with the use of EXXUA, including QT prolongation and serotonin syndrome, as part of its safety protocols[40] Other Financial Metrics - The company reported a derivative warrant liabilities loss of $8,244,000 for the quarter, compared to a gain of $3,016,000 in the previous year[54] - Other income, net, showed a loss of $(190), worsening from a loss of $(140) year-over-year[58] - The income tax benefit was not applicable in the current period, while there was a benefit of $(283) in the previous year[58]

Core Insights - The company reported total net revenue of $15.2 million for the fiscal 2026 second quarter [1] - Adjusted EBITDA was $(0.8) million, which includes investments of $30.0 million for the launch of EXXUA [1] - The company launched EXXUA™ (gepirone) extended-release tablets in December 2025, targeting the over $22 billion U.S. prescription major depressive disorder market [1] Financial Performance - Total net revenue for the quarter was $15.2 million [1] - Adjusted EBITDA was negative at $(0.8) million, reflecting the costs associated with the EXXUA launch [1] - The company had a cash balance of $30.0 million as of December 31, 2025 [1] Product Launch - EXXUA™ (gepirone) was launched in December 2025 as a key component of the company's commercial strategy [1] - The product aims to penetrate the significant U.S. market for major depressive disorder, valued at over $22 billion [1] Upcoming Events - The company will host a conference call and webcast on February 3, 2026, at 4:30 p.m. Eastern time to discuss the results [1]